WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events WU-CART-007 demonstrated preliminary evidence of anti-leukemic
First clinical data presented from WU-CART-007 program; data highlight promising safety profile and preliminary anti-tumor activity in patients with R/R T-ALL/LBL Additional clinical data showcase the ability of WU-NK-101 to engage the adaptive immune system and suggest the potential for durable effectivenes.
Cytokine-induced memory-like (CIML) NK cells engaged and activated endogenous adaptive immunity in the tumor microenvironment (TME) WU-NK-101 demonstrated PD-L1 and MHC-I checkpoint upregulation in solid tumor models Data highlight the potential of WU-NK-101 to reverse primary and acquired mechanisms of.
Acute Lymphocytic Leukemia (ALL) Cell Therapy Market Size Worth $2.3 billion in 2021 with the Highest Contribution from North America – GlobalData Pl